Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report

The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.

alt

Read more:

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

alt

Read more:

Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development

Boehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, will withdraw pending approval requests, and will not proceed with further work in this area due to rapid changes in the hepatitis C treatment environment.

alt

Read more:

Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs

Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.

alt

Read more:

European Regulators Give Positive Opinion on Daclatasvir for Hepatitis C

Bristol-Myers Squibb announced this week that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its hepatitis C virus (HCV) NS5A inhibitor daclatasvir, which has been given the brand name Daklinza.

alt

Read more: